Anti-TNF rescue CD4+Foxp3+ regulatory T cells in patients with type 1 diabetes from effects mediated by TNF

Cytokine. 2011 Sep;55(3):353-61. doi: 10.1016/j.cyto.2011.05.006.

Abstract

The presence of low-grade chronic inflammation is a known feature of long standing diabetes type 1. The association between serum level of several markers of inflammation and severity of DM1 was proven. Serum concentrations of TNF were reported to be elevated in diabetic patients, especially those who developed diabetic complications. Lately, it has been also shown that TNF may impair the subset of naturally arising regulatory T cells, which control autoimmunity. The presented study, for the first time, shows the regulatory T cells in the context of an inflammatory environment that is present in patients with type 1 diabetes. It indicates that TNF reduces the number and frequency of regulatory CD4(+)Foxp3(+) T cells in children with diabetes type 1 and that in vitro treatment with anti-TNF antibody seems to rescue this cell subset from its defective effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal
  • Apoptosis / immunology
  • Blood Glucose
  • CD28 Antigens / immunology
  • CD3 Complex / immunology*
  • CD4 Lymphocyte Count
  • Diabetes Mellitus, Type 1 / immunology*
  • Forkhead Transcription Factors / immunology
  • Humans
  • Inflammation
  • T-Lymphocytes, Regulatory / cytology
  • T-Lymphocytes, Regulatory / immunology*
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / immunology*
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Blood Glucose
  • CD28 Antigens
  • CD3 Complex
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Tumor Necrosis Factor-alpha